Vault Nano Inc. is biotechnology company developing and commercializing immune therapy for cancer and infectious diseases. Located in CNSI Incubator (California NanoSystems Institute) at UCLA , Vault Pharma's ImmunOncologyTM portfolio is a group of new medicines activating specific responses of the immune system to destroy cancer. Vault Nanos lead cancer drug, VNI-101, is a cytokine-based immune stimulant delivered by a novel human protein nanoparticle. Discovered by the Rome Laboratory at UCLA, the ImmunOncologyTM portfolio is based on a novel human protein nanoparticle, called a vault. VNIs therapies are designed to have clinical impact in multiple metastatic cancers.